C-Mannosylation supports folding and enhances stability of thrombospondin repeats

  1. Aleksandra Shcherbakova
  2. Matthias Preller
  3. Manuel H Taft
  4. Jordi Pujols
  5. Salvador Ventura
  6. Birgit Tiemann
  7. Falk F R Buettner
  8. Hans Bakker  Is a corresponding author
  1. Hannover Medical School, Germany
  2. Universitat Autònoma de Barcelona, Spain

Abstract

Previous studies demonstrated importance of C-mannosylation for efficient protein secretion. To study its impact on protein folding and stability, we analyzed both C-mannosylated and non-C-mannosylated thrombospondin type 1 repeats (TSRs) of netrin receptor UNC-5. In absence of C-mannosylation, UNC-5 TSRs could only be obtained at low temperature and a significant proportion displayed incorrect intermolecular disulfide bridging, which was hardly observed when C-mannosylated. Glycosylated TSRs exhibited higher resistance to thermal and reductive denaturation processes and the presence of C-mannoses promoted the oxidative folding of a reduced and denatured TSR in vitro. Molecular dynamics simulations supported the experimental studies and showed that C-mannoses can be involved in intramolecular hydrogen bonding and limit the flexibility of the TSR tryptophan-arginine ladder. We propose that in the endoplasmic reticulum folding process, C-mannoses orient the underlying tryptophan residues and facilitate the formation of the tryptophan arginine ladder, thereby influencing the positioning of cysteines and disulfide bridging.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 3, 4 and 5

Article and author information

Author details

  1. Aleksandra Shcherbakova

    Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4175-547X
  2. Matthias Preller

    Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7784-4012
  3. Manuel H Taft

    Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5853-8629
  4. Jordi Pujols

    Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
    Competing interests
    The authors declare that no competing interests exist.
  5. Salvador Ventura

    Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9652-6351
  6. Birgit Tiemann

    Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Falk F R Buettner

    Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8468-1223
  8. Hans Bakker

    Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany
    For correspondence
    bakker.hans@mh-hannover.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1364-9154

Funding

Deutsche Forschungsgemeinschaft (FOR2509 BA 4091/6-1)

  • Hans Bakker

Deutsche Forschungsgemeinschaft (BA 4091/5-1)

  • Hans Bakker

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Deborah Fass, Weizmann Institute of Science, Israel

Publication history

  1. Received: October 23, 2019
  2. Accepted: December 22, 2019
  3. Accepted Manuscript published: December 23, 2019 (version 1)
  4. Version of Record published: January 10, 2020 (version 2)

Copyright

© 2019, Shcherbakova et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,330
    Page views
  • 298
    Downloads
  • 48
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Aleksandra Shcherbakova
  2. Matthias Preller
  3. Manuel H Taft
  4. Jordi Pujols
  5. Salvador Ventura
  6. Birgit Tiemann
  7. Falk F R Buettner
  8. Hans Bakker
(2019)
C-Mannosylation supports folding and enhances stability of thrombospondin repeats
eLife 8:e52978.
https://doi.org/10.7554/eLife.52978

Further reading

    1. Biochemistry and Chemical Biology
    Holly Y Chen, Manju Swaroop ... Anand Swaroop
    Research Article

    Ciliopathies manifest from sensory abnormalities to syndromic disorders with multi-organ pathologies, with retinal degeneration a highly penetrant phenotype. Photoreceptor cell death is a major cause of incurable blindness in retinal ciliopathies. To identify drug candidates to maintain photoreceptor survival, we performed an unbiased, high-throughput screening of over 6,000 bioactive small molecules using retinal organoids differentiated from induced pluripotent stem cells (iPSC) of rd16 mouse, which is a model of Leber congenital amaurosis (LCA) type 10 caused by mutations in the cilia-centrosomal gene CEP290. We identified five non-toxic positive hits, including the lead molecule reserpine, which maintained photoreceptor development and survival in rd16 organoids. Reserpine also improved photoreceptors in retinal organoids derived from induced pluripotent stem cells of LCA10 patients and in rd16 mouse retina in vivo. Reserpine-treated patient organoids revealed modulation of signaling pathways related to cell survival/death, metabolism, and proteostasis. Further investigation uncovered dysregulation of autophagy associated with compromised primary cilium biogenesis in patient organoids and rd16 mouse retina. Reserpine partially restored the balance between autophagy and the ubiquitin-proteasome system at least in part by increasing the cargo adaptor p62, resulting in improved primary cilium assembly. Our study identifies effective drug candidates in preclinical studies of CEP290 retinal ciliopathies through cross-species drug discovery using iPSC-derived organoids, highlights the impact of proteostasis in the pathogenesis of ciliopathies, and provides new insights for treatments of retinal neurodegeneration.

    1. Biochemistry and Chemical Biology
    Lisa Goebel, Tonia Kirschner ... Daniel Rauh
    Short Report

    Mutations within Ras proteins represent major drivers in human cancer. In this study, we report the structure-based design, synthesis, as well as biochemical and cellular evaluation of nucleotide-based covalent inhibitors for KRasG13C, an important oncogenic mutant of Ras that has not been successfully addressed in the past. Mass spectrometry experiments and kinetic studies reveal promising molecular properties of these covalent inhibitors, and X-ray crystallographic analysis has yielded the first reported crystal structures of KRasG13C covalently locked with these GDP analogues. Importantly, KRasG13C covalently modified with these inhibitors can no longer undergo SOS-catalysed nucleotide exchange. As a final proof-of-concept, we show that in contrast to KRasG13C, the covalently locked protein is unable to induce oncogenic signalling in cells, further highlighting the possibility of using nucleotide-based inhibitors with covalent warheads in KRasG13C-driven cancer.